Ipsen announces publication in Pediatrics of the results of the phase III randomized study showing the efficacy and safety of Dysport® (abobotulinumtoxinA) in children with dynamic equinus foot deformity due to cerebral palsy

  • Single injections of both Dysport®
    (abobotulinumtoxinA) doses (10U/kg/leg and 15U/kg/leg) significantly
    reduce muscle hypertonia and spasticity translating into clinical and
    functional benefits

PARIS–(BUSINESS WIRE)–Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the scientific
journal Pediatrics published1 the detailed results of
the phase III randomized study (NCT01249417) showing both the efficacy
and the safety of Dysport® in the treatment of dynamic
equinus foot deformity (also known as pediatric lower limb spasticity),
a condition associated with cerebral palsy in children.

The study met the primary endpoint (Modified Ashworth Scale, MAS) and
the first secondary endpoint (Physician Global Assessment, PGA) in
children with dynamic equinus foot deformity who received injections of
Dysport® in the gastrocnemius and soleus calf muscles. Dysport®
showed statistically significant improvement in muscle tone, resulting
in an improved overall clinical benefit at week 4 at the two dose levels
tested (10 and 15U/kg for unilateral injection or 20 and 30U/kg for
bilateral injections). In addition, improvement of spasticity and
attainment of overall treatment goals were demonstrated in a
statistically and clinically significant manner as compared to placebo
at week 4 after injection. Both doses of Dysport® were well
tolerated and there was no evidence of a dose relationship for adverse
events. The most frequent treatment emergent adverse events were common
childhood infections (upper respiratory tract infections).

Claude Bertrand, Executive Vice President R&D and Chief Scientific
Officer, Ipsen
stated: “The peer-reviewed publication of these
Phase 3 results in the journal Pediatrics confirms the favorable
efficacy and safety profile of Dysport
® in the
treatment of lower limb spasticity in children with cerebral palsy and
demonstrates improvement in functional benefit after a single injection
of Dysport
®. The study results confirm the
therapeutic value of Dysport
® in this
debilitating condition, the most common cause of chronic motor
disability in childhood

Professor Mauricio Delgado, Director of the Pediatric Neurology
Department at Texas Scottish Rite Hospital for Children and Professor of
Neurology and Neurotherapeutics at the University of Texas Southwestern
Medical Center)
and Principal Investigator of the study stated:
“The publication of this study in Pediatrics is important news for
the field of pediatric neurorehabilitation and for the treatment of
children with equinus foot deformity due to cerebral palsy. This is the
first international study that demonstrates substantial improvements in
muscle tone and spasticity translating into clinical and functional
benefits after a single injection in this patient population. This study
both highlights the potential therapeutic value of Dysport
(abobotulinum toxin) in children with cerebral palsy and shows the
potential value of new assessment methods that could have practical
clinical application.”

About the Double Blind Phase 3 Study in cerebral palsy (hemiplegic
and diplegic) children with lower limb spasticity

The Phase III study (NCT01249417) was multi-center, prospective, double
blind, randomized, and placebo-controlled. It was conducted in the U.S.,
Mexico, Chile, Turkey, France and Poland.

A total of 241 patients from 27 centers were randomized to treatment
with Dysport® 10U/kg/leg (n=80), Dysport®
15U/kg/leg (n=80) or placebo (n=81). The purpose of this study was to
assess the efficacy of Dysport® compared to placebo in the
treatment of Lower Limb Spasticity in children with cerebral palsy.
Muscle tone and spasticity were assessed using the MAS and the Tardieu
Scale; patient functionality was assessed using the Physician’s Global
Assessment (PGA) and goal attainment scaling (GAS).

Study results showed a significant improvement versus placebo on muscle
tone at both doses at week 4 post-injection (Primary endpoint –
Assessment scale: Modified Ashworth Scale) with abobotulinumtoxinA; mean
[95%CI] treatment differences vs. placebo were: -0.49 [-0.75, -0.23]
(p=0.0002) for 15U/kg/leg and -0.38 [-0.64, -0.13] (p=0.003) for

A significant improvement was also observed on the overall clinical
improvement (first secondary endpoint – Physician Global Assessment)
with mean treatment differences vs. placebo of 0.77 [0.45, 1.10] for
15U/kg/leg and 0.82 [0.50, 1.14] for 10U/kg/leg (both p<0.0001).

In addition, significant improvement in spasticity (tertiary endpoint –
using the Tardieu scale) was observed at Week 4. Both doses improved the
Tardieu scale spasticity grade Y at 4 Weeks (p<0.001). For the
15U/kg/leg dose, Week 4 improvements were also accompanied by
significant improvements in the angle of catch XV3 (p=0.0003)
and angle of arrest XV1 (p=0.01).

The use of Goal Attainment Scale clearly demonstrates that improvements
in tone and spasticity allow the patients to achieve their overall
functional goals, namely those related to walking and gait patternat
both doses tested at Week 4.

Both doses of Dysport® were well tolerated and there was no
evidence of a dose relationship for adverse events (AEs). The most
frequent TEAEs (treatment emergent adverse events) were common childhood
infections (upper respiratory tract infections). Five patients in the
abobotulinumtoxinA groups had an AE of epilepsy recorded versus none in
the placebo group, however none was considered related to study
treatment and there was an over-representation of epilepsy in the
treatment groups.

After the completion of this double blind study, patients were offered
the option to continue in an open label long-term study where they would
receive additional treatment with Dysport®.

About Dysport®

Dysport® is an injectable form of botulinum toxin type A
(BTX-A), which is isolated and purified from Clostridium BTX-A bacteria.
It is supplied as a lyophilized powder.

Dysport® was first registered for the treatment of
blepharospasm and hemifacial spasm in the United Kingdom in 1990. It is
licensed in 82 countries for various indications including
blepharospasm, upper and lower limb spasticity in adults, hemifacial
spasm, spasmodic torticollis (also referred to as cervical dystonia),
lower limb spasticity due to cerebral palsy in children, axillary
hyperhidrosis and glabellar lines.

Dysport® is approved for the treatment of lower limb
spasticity in children in many European and international markets, but
not in the United States (USA). As such, data from studies of Dysport®
in children with lower limb spasticity are investigational in the USA.

About Ipsen

Ipsen is a global specialty-driven biotechnological group with total
sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in
more than 115 countries, with a direct commercial presence in 30
countries. Ipsen’s ambition is to become a leader in specialty
healthcare solutions for targeted debilitating diseases. Its development
strategy is supported by 3 franchises: neurology, endocrinology and
urology-oncology. Ipsen’s commitment to oncology is exemplified through
its growing portfolio of key therapies improving the care of patients
suffering from prostate cancer, bladder cancer or neuroendocrine tumors.
Ipsen also has a significant presence in primary care. Moreover, the
Group has an active policy of partnerships. Ipsen’s R&D is focused on
its innovative and differentiated technological platforms, peptides and
toxins, located in the heart of the leading biotechnological and life
sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US). In
2014, R&D expenditure totaled close to €187 million, representing about
15% of Group sales. The Group has more than 4,500 employees worldwide.
Ipsen’s shares are traded on segment A of Euronext Paris (stock code:
IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement
Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has
implemented a Sponsored Level I American Depositary Receipt (ADR)
program, which trade on the over-the-counter market in the United States
under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

Ipsen Forward Looking Statements

The forward-looking statements, objectives and targets contained herein
are based on the Group’s management strategy, current views and
assumptions. Such statements involve known and unknown risks and
uncertainties that may cause actual results, performance or events to
differ materially from those anticipated herein. All of the above risks
could affect the Group’s future ability to achieve its financial
targets, which were set assuming reasonable macroeconomic conditions
based on the information available today. Use of the words “believes,”
“anticipates” and “expects” and similar expressions are intended to
identify forward-looking statements, including the Group’s expectations
regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document were
prepared without taking into account external growth assumptions and
potential future acquisitions, which may alter these parameters. These
objectives are based on data and assumptions regarded as reasonable by
the Group. These targets depend on conditions or facts likely to happen
in the future, and not exclusively on historical data. Actual results
may depart significantly from these targets given the occurrence of
certain risks and uncertainties, notably the fact that a promising
product in early development phase or clinical trial may end up never
being launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. The Group must face or might face
competition from generic products that might translate into a loss of
market share. Furthermore, the Research and Development process involves
several stages each of which involves the substantial risk that the
Group may fail to achieve its objectives and be forced to abandon its
efforts with regards to a product in which it has invested significant
sums. Therefore, the Group cannot be certain that favourable results
obtained during pre-clinical trials will be confirmed subsequently
during clinical trials, or that the results of clinical trials will be
sufficient to demonstrate the safe and effective nature of the product
concerned. There can be no guarantees a product will receive the
necessary regulatory approvals or that the product will prove to be
commercially successful. If underlying assumptions prove inaccurate or
risks or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks and
uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation; global
trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new
product development, including obtaining regulatory approval; the
Group’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the
effectiveness of the Group’s patents and other protections for
innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions. The Group also depends on third
parties to develop and market some of its products which could
potentially generate substantial royalties; these partners could behave
in such ways which could cause damage to the Group’s activities and
financial results. The Group cannot be certain that its partners will
fulfil their obligations. It might be unable to obtain any benefit from
those agreements. A default by any of the Group’s partners could
generate lower revenues than expected. Such situations could have a
negative impact on the Group’s business, financial position or
performance. The Group expressly disclaims any obligation or undertaking
to update or revise any forward looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such statements
are based, unless so required by applicable law. The Group’s business is
subject to the risk factors outlined in its registration documents filed
with the French Autorité des Marchés Financiers.

1 online at http://pediatrics.aappublications.org/content/early/2016/01/24/peds.2015-2830
Delgado MR, Albright AL. Movement disorders in children: definitions,
classifications, and grading systems. J Child Neurol. 2003;18
Suppl 1:S1-8.
3 Aisen ML, Kerkovich D, Mast J, et al.
Cerebral palsy: clinical care and neurological rehabilitation. Lancet
4 Yeargin-Allsopp M, Van
Naarden Braun K, Doernberg NS, Benedict RE, Kirby RS, Durkin MS.
Prevalence of cerebral palsy in 8-year-old children in three areas of
the United States in 2002: a multisite collaboration. Pediatrics.


For further information:
Senior Vice-Président, Public Affairs and Communication
+33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
E-mail: didier.veron@ipsen.com

Stéphane Durant des Aulnois
Vice President,
Investor Relations
Tel.: +33 (0)1 58 33 60 09
Fax: +33 (0)1 58
33 50 63
E-mail: stephane.durant.des.aulnois@ipsen.com
Le Guennec
Corporate External Communication Manager
Tel.: +33
(0)1 58 33 51 17
Fax: +33 (0)1 58 33 50 58
E-mail : brigitte.le.guennec@ipsen.com